Madrigal Pharmaceuticals, Inc. (MDGL)
Automate Your Wheel Strategy on MDGL
With Tiblio's Option Bot, you can configure your own wheel strategy including MDGL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MDGL
- Rev/Share 14.3669
- Book/Share 32.1682
- PB 8.4422
- Debt/Equity 0.1685
- CurrentRatio 5.9077
- ROIC -0.5126
- MktCap 6029750181.0
- FreeCF/Share -18.1705
- PFCF -15.0214
- PE -15.3205
- Debt/Assets 0.1202
- DivYield 0
- ROE -0.5054
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | MDGL | B. Riley Securities | Neutral | Buy | $236 | $422 | Feb. 28, 2025 |
| Reiterated | MDGL | H.C. Wainwright | -- | Buy | $400 | $405 | Feb. 27, 2025 |
News
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - Chief Executive Officer and Director Mardi Dier - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Andrea Newkirk - Goldman Sachs Ritu Baral - TD Cowen Akash Tewari - Jefferies Yasmeen Rahimi - Piper Sandler Liisa Bayko - Evercore Jay Olson - Oppenheimer Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Operator Good day, and thank you for standing by.
Read More
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Read More
Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Madrigal (MDGL) came out with a quarterly loss of $3.32 per share versus the Zacks Consensus Estimate of a loss of $3.62. This compares to loss of $7.38 per share a year ago.
Read More
Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue?
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
Read More
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Positive
Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's Phase 3 trial aims to expand Rezdiffra's label to early cirrhosis by 2027, with EMA approval expected in mid-2025. GLP-1s like semaglutide and tirzepatide show promising MASH results, potentially disrupting Rezdiffra's market despite its first-mover advantage.
Read More
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Read More
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash position improved to $931m, and Rezdiffra's market potential remains significant with no current competitors. Positive study data and upcoming European approval could further boost Rezdiffra's market presence, making Madrigal a prime M&A target.
Read More
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports fourth-quarter and year-end 2024 financial results and reviews business highlights.
Read More
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.
Read More
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets.
Read More
About Madrigal Pharmaceuticals, Inc. (MDGL)
- IPO Date 2007-02-06
- Website https://www.madrigalpharma.com
- Industry Biotechnology
- CEO Mr. William J. Sibold
- Employees 528